Latest

How Data Science & Network Analytics Can Help Pharma Shift from Brand Centricity to Customer Centricity

Healthcare companies are overwhelming physicians and hospitals with brand messaging overlap. Let’s use data science to fix that, says Kevin Troyanos.

Drug Serialization for DSCSA Compliance Benefits Everyone

Despite delay in enforcement of Drug Supply Chain Security Act's new serialization requirement, getting compliant now is key.

Functional Service Partnerships: A Case Study for CRO Resource Management

A review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.

PharmExec Videos

New & Noteworthy

Pharm Exec's 16th Annual Industry Audit

Our latest review reveals that those companies scoring well on profit management metrics are best positioned to maintain that crucial edge in performance execution.

The Supply Chain: What Price Patient Centricity?

Can the pharma industry truly achieve a patient-centric supply chain? How some clinical trial logistics companies are racing ahead in making the patient a key link in the chain.

Critical Crossroads for Cold Chain Storage

Technology and other trends in medicine are driving the need for new strategies and investments in temperature sensitive packaging.

Leading With Patients in Mind: Cynthia Schwalm

Cynthia Schwalm, EVP and president of North American commercial operations for Ipsen, talks to Pharm Exec about the importance of stepping outside of the C-suite and into the world of the patient.

Data Inflection Point

The time is now for pharma to take next steps in tech adoption, writes Lance Scott.

The UK's Post-Brexit Life Sciences Strategy: Outlook and Implications

Neil Grubert reviews the UK’s post-Brexit life sciences strategy, with a particular focus on the key area of market access.

Sales & Marketing

How Data Science & Network Analytics Can Help Pharma Shift from Brand Centricity to Customer Centricity

Healthcare companies are overwhelming physicians and hospitals with brand messaging overlap. Let’s use data science to fix that, says Kevin Troyanos.

Survival/Success in the Age of Too Much Information

For marketers, getting messages out in the age of polarization and "TMI" requires common sense and courage, says Al Topin.

The 'Hear' and Now for Pharma and Social Media

For the life sciences industry in 2017, engaging across social media means less talking—and more listening. Peter Houston reports.

Featured E-Books

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. Download the e-book.

 

Bright Skies, Big Challenges: Orphan Drugs and Rare Diseases

From the editors of Pharmaceutical Executive, check out the latest e-book discussing the state and future of Rare and Orphan Diseases. Download the e-book.

 

Securing the Global Supply Chain: Strategies for Operational Excellence

Strategic management of the supply chain is vital to winning with customers. Cost and quality are important, but they are not the only things customers care about: New services, flexibility in  relationships, supply reliability, and creatively overcoming obstacles in delivery of products are also core values. Pharmaceutical product portfolios and customers are becoming more complex. To stay ahead, customer-focused supply-chain capabilities is becoming an increasingly crucial part of a company’s competitive advantage. Download the e-book.

 

View all e-books

PEspeaks

Email's All That

This article discusses email marketing opportunities through the lens of 1999's dramatic comedy, She's All That.

How to Use Data to Capture Value in Pharma

In the second of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Capture.

Can A New Value Framework Help Ease Friction Over Orphan Drug Prices?

Even on the contentious topic of orphan drug pricing, the last few months have brought hopeful signs that patients, pharmaceutical companies, health insurers, and the academic bodies that counsel them are trying to speak the same language.

You Are Pharma

A big thank you to you, our readers, for lending your voice to Pharm Exec's editorial mission—giving you the information you need and want. Click ahead for a look at some of the future topics we'll be tackling.

Compliance Top of Mind

There is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry. The articles from Pharmaceutical Executive provide a look at the latest in compliance for marketing, labeling, and export control, as well as offer tips to stay compliant in the coming years.
 

Read More.

Interviews

Health Policy Problem Solver: Fumie Griego

IFPMA's new Assistant Director General speaks about her mission to use the organization’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

The Man with a Price: ICER's Steven Pearson

Everyone’s talking value, but not everyone is willing to pin down the elusive concept. Pharm Exec talks with Steven Pearson, founder of the Institute for Clinical Effectiveness Review (ICER), about all things value-based.

Clinical-Stage Biotech Selects Collaborative Enterprise Tool

Edge Therapeutics’ Justin Zamirowski and EightSpokes’ Andy Mehrotra discuss how a new, collaborative approach to managing projects across the enterprise is improving time to market.

Improving Patients’ Lives and Boosting Mature Product Portfolios

Q&A with Merck KGaA’s Simon Sturge spotlights the development of one injection device that is helping change the treatment-adherence landscape.

Regulatory

Drug Serialization for DSCSA Compliance Benefits Everyone

Despite delay in enforcement of Drug Supply Chain Security Act's new serialization requirement, getting compliant now is key.

FDA, Industry Prepare for New User Fee Initiatives

Drug pricing, right-to-try, opioids, and OTC improvements still on legislative agenda. Jill Wechsler reports.

The UK's ‘New’ Statutory Scheme for Pricing of Branded Medicines

With a new consultation from the UK’s Department of Health proposing changes to the Statutory Scheme for Pricing of Branded Medicines, what could this mean for negotiation of a successor to the Pharmaceutical Price Regulation Scheme? Leela Barham reports.

Busy Congress Unlikely to Act on Drug Pricing Legislation This Fall

A long list of high priority issues requiring immediate attention on Capitol Hill leaves little time to consider drug access proposals that have limited bipartisan support, writes Jill Wechsler.

From the Editor

You Are Pharma

A big thank you to you, our readers, for lending your voice to Pharm Exec's editorial mission—giving you the information you need and want. Click ahead for a look at some of the future topics we'll be tackling.

Pharma’s Marijuana Makeover

As more states approve the use of medical marijuana—and its rising profile as potential opioid alternative—industry and FDA are stepping up their focus on developing cannabis-derived therapies.

The 1, 2, 3’s of VBCs

As we step further into the waters of value-based contracting arrangements, lessons learned must be shared—including the role of the patient in the equation.

lorem ipsum